Hardik Shah
2026.06.30 12:35

๐Ÿ“ข ๐‰๐”๐’๐“ ๐ˆ๐: FDA Accepts $Sarepta Therap(SRPT.US) Sarepta's sNDAs for AMONDYS 45 and VYONDYS 53

๐Ÿ‘‰ ๐Š๐ž๐ฒ ๐‡๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐ฌ:

โžค FDA accepted ๐’๐š๐ซ๐ž๐ฉ๐ญ๐š'๐ฌ sNDAs for ๐€๐Œ๐Ž๐๐ƒ๐˜๐’ ๐Ÿ’๐Ÿ“ and ๐•๐˜๐Ž๐๐ƒ๐˜๐’ ๐Ÿ“๐Ÿ‘.

โžค Applications seek to convert both therapies from ๐š๐œ๐œ๐ž๐ฅ๐ž๐ซ๐š๐ญ๐ž๐ to ๐ญ๐ซ๐š๐๐ข๐ญ๐ข๐จ๐ง๐š๐ฅ approval.

โžค FDA set a ๐๐ƒ๐”๐…๐€ action date of ๐…๐ž๐›. ๐Ÿ๐Ÿ–, ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ•.

โžค Filings are supported by ๐๐ก๐š๐ฌ๐ž ๐Ÿ‘ ๐„๐’๐’๐„๐๐‚๐„ data, real-world evidence, and safety results.

โžค ESSENCE missed its ๐ฉ๐ซ๐ข๐ฆ๐š๐ซ๐ฒ ๐ž๐ง๐๐ฉ๐จ๐ข๐ง๐ญ, but post-hoc analyses favored treatment.

โžค VYONDYS 53 was associated with a ๐Ÿ•.๐Ÿ“-๐ฒ๐ž๐š๐ซ delay in nighttime ventilation.

โžค AMONDYS 45 was associated with a ๐ฌ๐ญ๐š๐ญ๐ข๐ฌ๐ญ๐ข๐œ๐š๐ฅ๐ฅ๐ฒ ๐ฌ๐ข๐ ๐ง๐ข๐Ÿ๐ข๐œ๐š๐ง๐ญ slowing of lung function decline.

โžค More than ๐Ÿ,๐Ÿ–๐ŸŽ๐ŸŽ patients have received Sarepta's exon-skipping therapies worldwide.

๐Ÿ‘‰ ๐–๐ก๐ฒ ๐ˆ๐ญ ๐Œ๐š๐ญ๐ญ๐ž๐ซ๐ฌ:

โžค Traditional approval could strengthen the therapies' ๐ซ๐ž๐ ๐ฎ๐ฅ๐š๐ญ๐จ๐ซ๐ฒ standing and long-term availability.

โžค FDA acceptance marks a key ๐ซ๐ž๐ ๐ฎ๐ฅ๐š๐ญ๐จ๐ซ๐ฒ milestone for Sarepta's DMD franchise.

โžค Positive FDA decisions could support broader ๐ฉ๐ก๐ฒ๐ฌ๐ข๐œ๐ข๐š๐ง and payer confidence.

๐Ÿ‘‰ ๐„๐ฑ๐ฉ๐ž๐ซ๐ญ ๐’๐ญ๐š๐ญ๐ž๐ฆ๐ž๐ง๐ญ:

โžค "The submissions draw on the ESSENCE study and years of published real-world evidence, which together offer a fuller understanding of how these therapies benefit patients and change the progression of disease." โ€” ๐‹๐จ๐ฎ๐ข๐ฌ๐ž ๐‘๐จ๐๐ข๐ง๐จ-๐Š๐ฅ๐š๐ฉ๐š๐œ, Ph.D., President of Research and Development and Technical Operations at Sarepta Therapeutics.

The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.